O-0007SUBGROUP ANALYSES IN RAS MUTANT, BRAF MUTANT AND “ALL WT” METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH FOLFOXIRI PLUS BEVACIZUMAB (BEV) OR FOLFIRI PLUS BEV IN THE TRIBE STUDY